Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Boehringer Ingelheim To Present New Phase II Clinical Data On Two Lead Oncology Compounds At ASCO 2009
Boehringer Ingelheim will present new data on the company"s two lead oncology compounds, BIBW 2992* and BIBF 1120** at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), the company announced today. Two studies in the LUX-Lung clinical development programme for BIBW 2992 and a Phase II study of BIBF 1120 in ovarian cancer patients will be presented.
generic viagra online
University of Rhode Island Receives $18 Million Grant To Strengthen Biomedical Research Capacity In Rhode Island
The University of Rhode Island has been awarded a five-year, $18 million grant by a branch of the National Institutes of Health to strengthen biomedical research capacity in Rhode Island. One of the largest grants in the University"s history, the grant is the third in a series of multi-million dollar awards the agency has given URI for this purpose since 2001, for a total of $42 million.
News of the day
New Analysis Examines Fraud In Both Private And Public Health Insurance Markets
A new report from The George Washington University School of Public Health and Health Services, Department of Health Policy challenges the notion that fraud is a problem only in public health insurance markets and finds that fraud is a system-wide problem affecting private and public health insurance alike. The report finds that some of the most striking examples of fraud come from fraud committed directly by the private insurance industry itself. In 2007, when the U.S. spent nearly $2.3 trillion on health care and public and private insurers processed more than 4 billion health insurance claims, fraud was estimated to reach as much as 10 percent of annual health care spending. At this rate, the losses in 2007 alone over $220 billion would have been enough to cover the uninsured. The National Health Care Anti-Fraud Association (NHCAA) has estimated conservatively that 3 percent of all health care spending or $68 billion is lost to health care fraud.
Nutrition

TR BioSurgical, LLC Develops Breakthrough Osteoarthritis Implant

TR BioSurgical, LLC, announced highly encouraging results using their new medical device (bioscaffold) in canine patients with advanced osteoarthritis. The new bioscaffold is implanted in or near diseased tissue and provides a structural matrix for local repair cells, such as stem cells or fibroblasts, to attach and heal tissue by local, physiological repair mechanisms. The new bioscaffold implant contains no drugs, cells or growth factors and is eventually resorbed by the infiltrating cells. The implant is made from a proprietary, copolymerized collagen and is sterile, cost effective, and non- immunogenic. Dr. Charles Pullen, lead investigator at the Animal Medical and Surgical Center, Scottsdale, Arizona, stated, "We have been evaluating canine patients with moderate to severe degenerative joint disease and pain. Without exception the owners reported a marked improvement within seven days of implantation and continued improvement thereafter in all dogs implanted with the bioscaffold, even with the discontinuation of all arthritis drugs and supplements. Dogs which required heavy medication to walk very short distances are walking, jumping, and running long distances just as they did before the onset of osteoarthritis with just one implant procedure with the bioscaffold". Dr. Jeff Kellerman, VP of R&D at TR BioSurgical, further added, "Few would debate that veterinary medicine is long overdue for safer, more effective options for managing osteoarthritis. Many of the drugs used in veterinary medicine can have harmful side effects and achieve suboptimal clinical benefits. Our team has developed a novel, cost effective and safe bioscaffold that has achieved optimal clinical outcomes in dogs that are poorly responsive to medical management." About Canine Osteoarthritis Osteoarthritis is the leading cause of disability in dogs and is estimated to affect twenty five percent of the dog population, making it one of the single largest markets in veterinary medicine. Osteoarthritis is a complex disorder involving cartilage, subchondral bone, and synovium leading to various degrees of inflammation and physical disability. Canine arthritis can mimic the progressive inflammatory and structural changes observed in human osteoarthritis, making it an excellent comparative model for human orthopedics and degenerative joint disease. TR BioSurgical, LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009